Shots:
- Frontier to receive ~$100M including $55M upfront and remaining as milestones within the first 12mos. of collaboration and is eligible for development & commercial milestone that could exceed $1B, along with royalties on commercialized products
- Following the completion of pre-clinical development, AbbVie will lead global development and commercialization activities and costs for the programs whereas Frontier will retain an option to share development activities and expenses for certain oncology programs through the completion of P-II
- AbbVie retains the right to expand the collaboration in the future by exercising options to a defined number of additional targets
Click here to read full press release/ article | Ref: Abbvie | Image: Stat
The post AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets first appeared on PharmaShots.
